ECSP20034868A - Conjugados anticuerpo anti-cd40-fármaco - Google Patents
Conjugados anticuerpo anti-cd40-fármacoInfo
- Publication number
- ECSP20034868A ECSP20034868A ECSENADI202034868A ECDI202034868A ECSP20034868A EC SP20034868 A ECSP20034868 A EC SP20034868A EC SENADI202034868 A ECSENADI202034868 A EC SENADI202034868A EC DI202034868 A ECDI202034868 A EC DI202034868A EC SP20034868 A ECSP20034868 A EC SP20034868A
- Authority
- EC
- Ecuador
- Prior art keywords
- antibody conjugates
- drug antibody
- antibody
- formula
- drug conjugates
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593807P | 2017-12-01 | 2017-12-01 | |
| US201762595045P | 2017-12-05 | 2017-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20034868A true ECSP20034868A (es) | 2020-08-31 |
Family
ID=66663861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202034868A ECSP20034868A (es) | 2017-12-01 | 2020-06-29 | Conjugados anticuerpo anti-cd40-fármaco |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220265842A1 (enExample) |
| EP (1) | EP3716982A4 (enExample) |
| JP (1) | JP2021504430A (enExample) |
| KR (1) | KR20200095493A (enExample) |
| CN (1) | CN111465399A (enExample) |
| AU (1) | AU2018374633A1 (enExample) |
| BR (1) | BR112020010691A2 (enExample) |
| CA (1) | CA3081559A1 (enExample) |
| CL (1) | CL2020001442A1 (enExample) |
| CR (1) | CR20200285A (enExample) |
| DO (1) | DOP2020000119A (enExample) |
| EC (1) | ECSP20034868A (enExample) |
| IL (1) | IL274650A (enExample) |
| MX (1) | MX2020005465A (enExample) |
| PE (1) | PE20201464A1 (enExample) |
| PH (1) | PH12020550551A1 (enExample) |
| RU (1) | RU2020117156A (enExample) |
| SG (1) | SG11202004865SA (enExample) |
| WO (1) | WO2019106608A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021008305A (es) | 2019-01-11 | 2021-08-24 | Novartis Ag | Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa. |
| CN116761820A (zh) * | 2021-02-04 | 2023-09-15 | 上海森辉医药有限公司 | 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用 |
| TW202304464A (zh) * | 2021-03-23 | 2023-02-01 | 美商美國禮來大藥廠 | 新穎糖皮質素受體激動劑 |
| CN117043172A (zh) * | 2021-03-23 | 2023-11-10 | 伊莱利利公司 | 糖皮质激素受体激动剂 |
| AR125079A1 (es) | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Agonistas de receptores de glucocorticoides sustituidos con carboxi |
| AU2022242757B2 (en) * | 2021-03-23 | 2024-12-05 | Eli Lilly And Company | Glucocorticoid receptor agonists |
| WO2022268176A1 (zh) * | 2021-06-24 | 2022-12-29 | 江苏先声药业有限公司 | 甾体类化合物、其药物组合物及其应用 |
| WO2023025248A1 (zh) * | 2021-08-26 | 2023-03-02 | 映恩生物制药（苏州）有限公司 | 一种甾体化合物及其缀合物 |
| WO2023040793A1 (zh) * | 2021-09-14 | 2023-03-23 | 映恩生物制药（苏州）有限公司 | 一种抗炎症的化合物及其用途 |
| TWI896987B (zh) | 2022-06-16 | 2025-09-11 | 美商艾伯維生物醫療股份有限公司 | 抗ｃｄ１９抗體藥物接合物 |
| US20240218011A1 (en) | 2022-07-21 | 2024-07-04 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
| KR20250068745A (ko) * | 2022-09-22 | 2025-05-16 | 일라이 릴리 앤드 캄파니 | 글루코코르티코이드 수용체 효능제 |
| TW202432588A (zh) * | 2022-12-28 | 2024-08-16 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種cd40結合分子的組成物及醫藥用途 |
| TW202430226A (zh) * | 2022-12-28 | 2024-08-01 | 大陸商上海盛迪醫藥有限公司 | 抗cd40抗體藥物偶聯物、其製備方法及其醫藥用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201070535A1 (ru) * | 2007-11-30 | 2010-12-30 | Пфайзер Лимитед | Новые агонисты глюкокортикоидных рецепторов |
| PE20091525A1 (es) * | 2007-12-21 | 2009-09-25 | Schering Corp | Agonista del receptor glucocorticoide c-20-c21 sustituido |
| AU2012249454B2 (en) * | 2011-04-29 | 2016-03-24 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| US10550190B2 (en) * | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
| JP6518917B2 (ja) * | 2015-05-29 | 2019-05-29 | アッヴィ・インコーポレイテッド | 抗ｃｄ４０抗体およびその使用 |
| RS62040B1 (sr) * | 2016-06-02 | 2021-07-30 | Abbvie Inc | Agonist receptora glukokortikoida i njegovi imunokonjugati |
-
2018
- 2018-11-29 US US16/768,616 patent/US20220265842A1/en not_active Abandoned
- 2018-11-29 SG SG11202004865SA patent/SG11202004865SA/en unknown
- 2018-11-29 EP EP18883152.3A patent/EP3716982A4/en not_active Withdrawn
- 2018-11-29 CA CA3081559A patent/CA3081559A1/en active Pending
- 2018-11-29 BR BR112020010691-7A patent/BR112020010691A2/pt not_active Application Discontinuation
- 2018-11-29 KR KR1020207017805A patent/KR20200095493A/ko active Pending
- 2018-11-29 JP JP2020529611A patent/JP2021504430A/ja not_active Ceased
- 2018-11-29 PE PE2020000592A patent/PE20201464A1/es unknown
- 2018-11-29 WO PCT/IB2018/059480 patent/WO2019106608A1/en not_active Ceased
- 2018-11-29 AU AU2018374633A patent/AU2018374633A1/en not_active Abandoned
- 2018-11-29 CN CN201880077793.3A patent/CN111465399A/zh active Pending
- 2018-11-29 MX MX2020005465A patent/MX2020005465A/es unknown
- 2018-11-29 CR CR20200285A patent/CR20200285A/es unknown
- 2018-11-29 RU RU2020117156A patent/RU2020117156A/ru unknown
-
2020
- 2020-05-04 PH PH12020550551A patent/PH12020550551A1/en unknown
- 2020-05-13 IL IL274650A patent/IL274650A/en unknown
- 2020-05-29 CL CL2020001442A patent/CL2020001442A1/es unknown
- 2020-06-15 DO DO2020000119A patent/DOP2020000119A/es unknown
- 2020-06-29 EC ECSENADI202034868A patent/ECSP20034868A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20201464A1 (es) | 2020-12-17 |
| DOP2020000119A (es) | 2020-08-31 |
| AU2018374633A1 (en) | 2020-05-21 |
| MX2020005465A (es) | 2020-09-07 |
| SG11202004865SA (en) | 2020-06-29 |
| EP3716982A1 (en) | 2020-10-07 |
| IL274650A (en) | 2020-06-30 |
| WO2019106608A1 (en) | 2019-06-06 |
| RU2020117156A (ru) | 2022-01-04 |
| CR20200285A (es) | 2020-09-04 |
| JP2021504430A (ja) | 2021-02-15 |
| BR112020010691A2 (pt) | 2020-11-10 |
| CN111465399A (zh) | 2020-07-28 |
| EP3716982A4 (en) | 2021-08-11 |
| PH12020550551A1 (en) | 2021-03-22 |
| KR20200095493A (ko) | 2020-08-10 |
| US20220265842A1 (en) | 2022-08-25 |
| CL2020001442A1 (es) | 2020-09-11 |
| CA3081559A1 (en) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20034868A (es) | Conjugados anticuerpo anti-cd40-fármaco | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CL2021001706A1 (es) | Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326) | |
| MX2020008772A (es) | Conjugados de il-15, y sus usos. | |
| CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
| EA201990615A1 (ru) | Пирролобензодиазепиновые конъюгаты | |
| EA201791550A1 (ru) | Димеры бензодиазепинов, их конъюгаты и способы их получения и применения | |
| EP4488286A3 (en) | Saccharide-polypeptide conjugate compositions and methods of use thereof | |
| MX2019004690A (es) | Constructos de anticuerpos. | |
| MX2017007585A (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| MX373280B (es) | Anticuerpos anti-egfrviii y usos de los mismos. | |
| UY36401A (es) | Conjugados anticuerpos-fármacos | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| BR112021015477A2 (pt) | Anticorpos anti-cd228 e conjugados anticorpo-fármaco | |
| MX2022014457A (es) | Formulaciones de inmunoconjugado anti-cd79b estables. | |
| ECSP21068097A (es) | Anticuerpos claudina 6 y usos de los mismos | |
| BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
| BR112023024837A2 (pt) | Anticorpos anti-ccr8 | |
| CO2019013718A2 (es) | Anticuerpos anti-trkb | |
| CO2022003742A2 (es) | Conjugados de interleuquina 10 y sus usos | |
| MX2024004299A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos. | |
| CO2019011980A2 (es) | Formas cristalinas de (s)-afoxolaner | |
| BR112018012884A2 (pt) | novos anticorpos anti-mmp16 e métodos de uso | |
| CL2023000894A1 (es) | Compuestos de heteroarilo fusionados y su uso como inhibidores de camkii | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. |